EMA committee recommends approval of GSK’s RSV vaccine, Arexvy for all adults 18 years and older: London, UK Saturday, December 13, 2025, 13:00 Hrs [IST] GSK plc announced that ...

Arexvy is GSK’s adjuvanted recombinant vaccine designed to prevent lower respiratory tract disease (LRTD) caused by RSV. Initially approved for adults aged 60 and older, as well as those aged 50-59 ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

GSK secures FDA approval for its oral gonorrhoea drug as EMA backs expanded RSV vaccine and additional respiratory treatments ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed seven new medicines for approval this ...

GSK said on Friday a panel ‍of the European Medicines Agency had backed the use of its ‌respiratory syncytial ‌virus (RSV) ...

GSK (GSK) stock is in focus as an expert panel of the European Medicines Agency ((EMA)) endorses the company's Arexvy RSV ...

The recommendation by the CHMP should now result in approval of Arexvy in the broader age range in February next year, and ...

GSK said on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use had recommended ...

Arexvy targets recombinant respiratory syncytial virus, a contagious disease which affects the lungs, and is diagnosed in roughly 64 million people annually, according to research cited by GSK. The ...

OPEN The FTSE 100 was expected to open 41.1 points higher ahead of the bell on Friday after wrapping up the previous session ...

Investing.com -- GSK plc (LSE:GSK) announced Friday that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the indication of its RSV ...